CPD

Clinical Pearls: Getting Low-Density Lipoprotein-Cholesterol Levels to Target and Keeping Them There

Authors: Alberico L. Catapano, PhD, MD (h.c.); Brian A. Ference, MD, MPhil, MSc, FACC, FESC; Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC; Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE; Eric S.G. Stroes, MD, PhD; Alberto Zambon, MD, PhD, FAHA
CPD Released: 6/29/2023
Valid for credit through: 6/29/2024, 11:59 PM EST

Credits Available

Non-US Physicians - maximum of 0.75 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of cardiologists, primary care physicians, endocrinologists/diabetologists, nephrologists, and nurses.

The goal of this activity is for the learner to be better able to treat patients with lipid-lowering therapy to achieve and maintain LDL-C goals to reduce atherosclerotic cardiovascular disease (ASCVD) risk.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Adverse outcomes associated with failure to achieve appropriate LDL-C goals
- Lipid-lowering therapy required to achieve LDL-C goals
Have greater competence related to
- Achieving LDL-C goals and maintaining it for the long term

Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Moderator

Alberico L. Catapano, PhD, MD (h.c.)

Professor of Pharmacology
Director, Center of Epidemiology and Preventive Pharmacology
Director, Laboratory of Lipoproteins, Immunity and Atherosclerosis
Department of Pharmacological and Biomolecular Sciences
Director, Center for the Study of Atherosclerosis at Bassini Hospital
University of Milan and IRCCS MultiMedica
Milan, Italy

Disclosures

Alberico L. Catapano, PhD, MD (h.c.), has the following relevant financial relationships:
Consultant or advisor for: Menarini; Merck; Mylan Laboratories Inc.; Novartis; Sanofi
Speaker or member of speakers bureau for: Amgen Inc.; Amryt; Daiichi Sankyo, Inc.; Merck; Mylan Laboratories Inc.; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi
Research funding from: Mylan

Faculty

Brian A. Ference, MD, MPhil, MSc, FACC, FESC

Professor
Director, Research in Translational Therapeutics
Executive Director, Centre for Naturally Randomized Trials
University of Cambridge
Cambridge, United Kingdom

Disclosures

Brian A. Ference, MD, MPhil, MSc, FACC, FESC, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; AstraZeneca; CiVi Biopharma, Inc.; Daiichi Sankyo, Inc.; DalCor Pharmaceuticals; Eli Lilly; Ionis Pharmaceuticals; KrKa Pharmaceuticals; Merck; Mylan Laboratories Inc.; New Amsterdam Pharmaceuticals; Novartis; Novo Nordisk; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; The Medicines Company; Viatris
Speaker or member of speakers bureau for: Amgen Inc.; AstraZeneca; CiVi Biopharma, Inc.; Daiichi Sankyo, Inc.; DalCor Pharmaceuticals; Eli Lilly; Ionis Pharmaceuticals; KrKa Pharmaceuticals; Merck; Mylan Laboratories Inc.; Novartis; Novo Nordisk; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; The Medicines Company; Viatris
Research funding from: Amgen Inc.; Esperion Therapeutics, Inc.; Merck; Novartis; Pfizer, Inc.

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Professor of Medicine
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women's Heart Center
Anita D. Friedman Chair in Cardiovascular Medicine and Research
Smidt Heart Institute at Cedars-Sinai Medical Center
Los Angeles, California, United States

Disclosures

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, has the following relevant financial relationships:
Consultant or advisor for: Novartis
Speaker or member of speakers bureau for: Medtronics; Siemens Healthcare Diagnostics Inc.

Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE

Visiting Professor of General Practice
General Practitioner
University of Huddersfield
Clinical Consultant at Patient.info
Medical Broadcaster
Huddersfield, United Kingdom

Disclosures

Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE, has the following relevant financial relationships:
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme GmbH; Moderna, Inc.; Novartis

Eric S.G. Stroes, MD, PhD

Professor of Vascular Medicine
Amsterdam University Medical Centers
University of Amsterdam
Amsterdam, The Netherlands

Disclosures

Eric S.G. Stroes, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Esperion Therapeutics, Inc.; Merck; Novartis
Speaker or member of speakers bureau for: Akcea Therapeutics-Ionis Pharmaceuticals; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Esperion Therapeutics, Inc.; Merck; Novartis; Novo Nordisk; Sanofi-Regeneron Pharmaceuticals, Inc.
Research funding from: Ionis Pharmaceuticals; Novo Nordisk

Alberto Zambon, MD, PhD, FAHA

Associate Professor of Medicine
Department of Medicine
University of Padua School of Medicine
Padua, Italy

Disclosures

Alberto Zambon, MD, PhD, FAHA, has the following relevant financial relationships:
Consultant or advisor for: Amarin Corporation plc
Speaker or member of speakers bureau for: Abbott; Alfasigma USA, Inc.; Amarin Corporation plc; Amgen Inc.; Amryt; AstraZeneca; Fidia Pharma USA, Inc.; Mylan Laboratories Inc.; Novartis; Sanofi; SERVIER; Swedish Orphan Biovitrum; Zentiva

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Clinical Pearls: Getting Low-Density Lipoprotein-Cholesterol Levels to Target and Keeping Them There

Authors: Alberico L. Catapano, PhD, MD (h.c.); Brian A. Ference, MD, MPhil, MSc, FACC, FESC; Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC; Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE; Eric S.G. Stroes, MD, PhD; Alberto Zambon, MD, PhD, FAHAFaculty and Disclosures

CPD Released: 6/29/2023

Valid for credit through: 6/29/2024, 11:59 PM EST

processing....

Contents of This CPD Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

LDL-C Goals and Evidence-Based Guidelines

Dr Catapano introduces the program and reviews LDL-C goals.
Alberico L. Catapano, PhD, MD (h.c.)

Modifying ASCVD Risk in the Clinic

Dr Ference discusses the relationship between LDL-C reduction and ASCVD risk.
Brian A. Ference, MD, MPhil, MSc, FACC, FESC

Lipid-Lowering Therapy to Achieve Adequate LDL-C Reduction

Dr Gulati outlines lipid-lowering therapies to meet and maintain LDL-C goals.
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Maintaining LDL-C Goals Long Term: Importance of Physician-Patient Communication

Dr Jarvis discusses shared decision-making to achieve good medication adherence.
Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE

Preventing Recurrent ASCVD Events in Clinical Practice: Meet Peter

Dr Stroes reviews the clinical approach to lipid-lowering therapy for this patient.
Eric S.G. Stroes, MD, PhD

Long-Term Prevention of ASCVD in High-Risk Patients: Meet Maria

Dr Zambon reviews the clinical approach to lipid-lowering therapy for this patient.
Alberto Zambon, MD, PhD, FAHA

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 9

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Alberico L. Catapano, PhD, MD (h.c.)

Faculty

Brian A. Ference, MD, MPhil, MSc, FACC, FESC

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE

Eric S.G. Stroes, MD, PhD

Alberto Zambon, MD, PhD, FAHA

Editor

Anne M. Sendaydiego, PharmD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer:

CPD

Clinical Pearls: Getting Low-Density Lipoprotein-Cholesterol Levels to Target and Keeping Them There

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Alberico L. Catapano, PhD, MD (h.c.)

Faculty

Brian A. Ference, MD, MPhil, MSc, FACC, FESC

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Sarah Jarvis, MA (Cantab), BM, BCh (Oxon), DRCOG, FRCGP, MBE

Eric S.G. Stroes, MD, PhD

Alberto Zambon, MD, PhD, FAHA

Editor

Anne M. Sendaydiego, PharmD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer:

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Clinical Pearls: Getting Low-Density Lipoprotein-Cholesterol Levels to Target and Keeping Them There

Contents of This CPD Activity

LDL-C Goals and Evidence-Based Guidelines

Modifying ASCVD Risk in the Clinic

Lipid-Lowering Therapy to Achieve Adequate LDL-C Reduction

Maintaining LDL-C Goals Long Term: Importance of Physician-Patient Communication

Preventing Recurrent ASCVD Events in Clinical Practice: Meet Peter

Long-Term Prevention of ASCVD in High-Risk Patients: Meet Maria

Educational Impact Challenge